DRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde

Size: px
Start display at page:

Download "DRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde"

Transcription

1 WellDyneRx 34% 1 2% Inflammatory Con Diabetes MS Oncology Asthma/COPD High Blood Pressu HIV Pain/inflammation High Blood Choles Attention Disorde Inflammatory Con Diabetes MS Oncology Asthma/COPD High Blood Pressu Hypertension Hpertension Pain/inflammation Pain/inflammation

2 Every Little Thing Brings BIG OUTCOMES. WellDyneRx is a full-service, independent Pharmacy Benefit Manager (PBM) that makes the little things matter for our clients, employees, partners, and members. Because we are an independent PBM meaning we are not owned by a pharmacy, drug company, or health insurance provider we are able to negotiate freely on your behalf to keep costs low and quality of care high for our clients and members. As early pioneers in clinical pharmacy, WellDyneRx has a history of caring for patients differently and always from a pharmacological perspective. We don t just fill prescriptions. We constantly monitor our clients claims and optimize our formularies to match members with treatments and clinical programs that are effective and economical. Most of all, our clients value the flexibility and customization they get with WellDyneRx. Whatever you need, we can create the right plan for you. Custom solutions for maximum flexibility, because everything we do on your behalf adds up for our clients and members. Every little thing brings big outcomes. Drug Trend Report 2

3 Improved patient outcomes and lower costs are our specialty. In our wide variety of clinical programs has resulted in keeping overall trend to 1.2%, despite significant increases in utilization of specialty medications and double digit price inflation in many drug categories. Specialty medications account for almost 36% of overall spend but are attributed to only 0.8% claims. With a disproportionately large number of specialty pharmaceuticals in the pipeline, particularly targeted therapies in oncology, the specialty drug spend is anticipated to increase over the next several years. Our Intercept program, a strategic solution related to manufacturer copay cards, is designed to allow clients to mitigate these substantial increases without restricting access for these small patient populations with complex diseases. In, 48% of Intercept clients saw overall negative specialty trend despite increases in utilization. Overall, Intercept clients saw a 65% lower overall specialty trend than the 1.2% WellDyneRx book of business, and members saw a 60% cost-share reduction. According to the World Health Organization, increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments. US Specialty Care, winner of the Specialty Pharmacy Patient Choice Award, demonstrates excellence by driving medication adherence and specialty pharmacy patient and provider support. Our proven approach to drive medication OVERALL : WellDyneRx clients experienced an overall 1.2% increase in per member per year (PMPY) costs from 2016 to. adherence, identify and intervene on treatment issues, and improve provider care coordination through multiple touchpoints bolsters the percentage of patients who are adherent with their complex treatment regimens. Drug Trend Report 3

4 WellManaged Clinical Programs Make all the Difference. Clinical pharmacy expertise is at the core of all WellDyneRx solutions. We offer an industry-leading array of clinical programs called WellManaged that perfectly balance optimal clinical outcomes with minimized plan costs. From offerings that effectively treat diabetes, to programs that reduce the risks associated with high dose opioid use, the WellManaged suite of clinical solutions are evidence-based and promote high quality care. Diabetes is the leading cost driver in traditional drug spend, for both large and small plans, accounting on average for more than 10% of total drug spend and these numbers continue to rise as the diabetes epidemic continues. WellManaged-Diabetes with Case Management, one of our new clinical programs rolled out in July, provides a comprehensive approach to diabetes patient care designed to improve overall patient outcomes while controlling costs. Our program helps clients better manage diabetes costs through improved medication adherence, aggressive cost containment through tight formulary management and therapeutic interchange initiatives, improved therapeutic outcomes through monitoring of key outcome measures, and increased communication with prescribers to better coordinate care. Comparing the first six months of to the last six months of the same year, our program has helped clients have a negative unit cost trend while increasing medication adherence and reducing hemoglobin A1c, the primary health outcome related to the management of diabetes. WellDyneRx is also helping clients advocate for the safe and effective treatment of chronic pain. The Centers for Disease Control (CDC) attributes the dramatic spike in opioid-related overdose deaths to prescription opioid pain relievers. The President declared a national emergency around the opioid epidemic, and for the first time since the 1960s, the CDC has decreased the overall life expectancy due to the large numbers of needless opioid-related deaths. Since 2014, WellManaged-Opioids has helped clients mitigate rising inappropriate opioid prescribing and use without preventing appropriate access to medications used to relieve pain. Clients who implemented WellManaged-Opioids in 2014 saw a 50% reduction in opioid prescribing, 46% less high risk utilizers, and 42% lower opioid per member per month (PMPM), in an environment with increased media, regulatory, and medical establishment scrutiny. Despite the increased awareness, the opioid issue remains prevalent and WellManaged-Opioids maintains access to these medications while prioritizing patient safety and controlling costs. Drug Trend Report 4

5 Components of Trend Commercial plans saw per-person overall spending increase of only 1.2% Specialty experienced an increase in utilization due to expanded indications, new drugs to market, and large emphasis on moving specialty medications from the medical benefit to the pharmacy benefit, particularly Stelara and Remicade. Specialty accounted for 35.7% of overall spend in, an increase from 30.6% of overall spend in As expected, specialty spend will continue to increase as a percentage of overall spend due to new agents to market, expanded medications, and improved tolerability. Traditional unit cost decrease was driven by new generics in the highly utilized therapeutic classes of high blood pressure and high blood cholesterol. The Generic Dispensing Rate (GDR) across our clients increased from 82.68% in 2016 to 84.91% in. In addition to the new generics that came to market, this increase was augmented by over 30% of our clients who have implemented WellManaged- Generics. Many plans have implemented WellManaged-Opioids, which also helped drive a decrease in unit cost and utilization of opioid products, contributing to the decreases seen in the traditional spend. Plans that implemented WellManaged- Opioids in 2016 experienced a 27% reduction in utilization of opioids, 5.5% reduction in unit cost, and an overall opioid trend reduction of 31%. Utilization Unit Cost Total Trend Specialty 18.1% -0.2% 17.9% Traditional 0.4% -6.6% -6.2% Total 0.6% 0.6% 1.2% Drug Trend Report 5

6 Top Drugs by Spend Diabetes accounts for half of the top 10 traditional drugs by spend, with both oral and injectable agents. New agents in existing diabetes drug classes, such as Ozempic and Steglatro, will allow for expanded price competition among comparable clinically equivalent agents. Generic Viagra, which became available in late, is expected to demonstrate significant decreases in unit cost in A shift from Cialis to generic Viagra is also likely to occur, particularly with clients who have implemented WellManaged-Generics. Medications used to treat in ammatory conditions account for 60% of the top specialty drugs by spend. Agents used to treat inflammatory conditions are expected to claim more top ten specialty spots in Utilization shifts in Hepatitis C treatment to less expensive Mavyret will likely displace Zepatier from the top 10 specialty drug list by spend. TRADITIONAL Rank Product Name Therapy Class 1 JANUVIA Diabetes 2 CIALIS Erectile Dysfunction 3 LANTUS SOLOSTAR Diabetes 4 LYRICA Pain/Inflammation 5 VYVANSE Attention Disorder 6 VIAGRA Erectile Dysfunction 7 VICTOZA Diabetes 8 INVOKANA Diabetes 9 SYMBICORT Asthma/COPD 10 TRULICITY Diabetes SPECIALTY Rank Product Name Therapy Class 1 HUMIRA PEN Inflammatory Conditions 2 ENBREL SURECLICK Inflammatory Conditions 3 STELARA Inflammatory Conditions 4 TECFIDERA MS 5 COPAXONE MS 6 HUMIRA Inflammatory Conditions 7 NORDITROPIN FLEXPRO Growth Hormone 8 ENBREL Inflammatory Conditions 9 ZEPATIER Hep C 10 OTEZLA Inflammatory Conditions Drug Trend Report 6

7 Top 10 Therapeutic Categories Inflammatory conditions and diabetes are the predominant therapeutic categories, accounting for approximately 25% of overall drug spend in. Diabetes and Inflammatory conditions swapped positions from the previous year. This is largely due to the large increase in utilization of mediations in Inflammatory conditions with a shift from the medical to the pharmacy benefit. High Blood Cholesterol experienced a significant drop in rank, from number 4 in 2016 to number 9 in. This is due to the continued competition amongst statin agents, particularly reductions in spend for atorvastatin generic and the introduction of Crestor generic. Oncology moved up in the ranking from 7th place to 4th place, predominantly due to expanded indications for existing oncolytics, as well as several new chemical entities in, which drove double-digit increase in utilization. Benicar (olmesartan) and Crestor (rosuvastatin) generics significantly drove down unit cost in the high blood pressure and high blood cholesterol categories. Decreases in utilization of opioids and shifts to non hyper-inflated NSAIDs drove down trend for the pain/ inflammation category. Hepatitis C was not in the top therapeutic categories, driven largely by decreases in utilization and unit cost through our Hepatitis C Indication Based Formulary. HIV increased to rank 7 from previous year at rank 13. This is largely due to increased utilization of better tolerated agents with less side effects and drug-drug interactions. Rank Type Category PMPY Spend % OF TOTAL SPEND UTILIZATION UNIT COST TOTAL 1 Specialty Inflammatory Conditions $ % 22.8% 13.8% 36.6% 2 Traditional Diabetes $ % 3.6% 2.2% 5.8% 3 Specialty MS $ % -1.2% 6.9% 5.7% 4 Specialty Oncology $ % 20.6% 6.4% 27.0% 5 Traditional Asthma/COPD $ % 3.7% -2.5% 1.2% 6 Traditional High Blood Pressure $ % -0.3% -18.6% -18.9% 7 Specialty HIV $ % 13.8% 14.9% 28.7% 8 Traditional Pain/Inflammation $ % -7.3% -26.0% -33.3% 9 Traditional High Blood Cholesterol $ % -0.1% -38.8% -38.9% 10 Traditional Attention Disorder $ % 3.1% -3.3% -0.2% $ % -0.1% -3.9% -4.0% Total $ 1, % 0.6% 0.6% 1.2% Drug Trend Report 7

8 1. Inflammatory Conditions SPECIALTY CONDITION Humira and Enbrel products account for 60% of market share and experienced AWP increases nearing 10%, which contributed to both unit cost and overall trend increase in this category. While biosomilars for Enbrel and Humira have been approved by the FDA, due to ongoing patent litigation, it is unlikely they will enter the market in 2018 thus delaying potential price competition amongst agents. Stelara and Remicade experienced significant increases in utilizers due to increased benefit design change moving coverage from the medical to pharmacy specialty benefit. Utilization increase in this category is cut approximately in half from 22.8% to 11.8% if Stelara and Remicade are removed from the category. Dupixent, the first specialty drug for treatment of atopic dertatitis, saw significant utilization and is expected to increase in market share for the category for Dupixent has also filed with the FDA seeking expanded indication for asthma as add-on therapy. A decision is expected in late 2018 and could result in increase of utilization of this agent. Two oral agents for inflammatory conditions, Xeljanz XR and Otezla, experienced increases in utilization and market share. MARKET SHARE HUMIRA PEN HUMIRA STELARA ENBREL SURECLICK OTEZLA CATEGORY PMPY SPEND % OF TOTAL SPEND UTILIZATION UNIT COST TOTAL Inflammatory Conditions $ % 22.8% 13.8% 36.6% Drug Trend Report 8

9 2. Diabetes TRADITIONAL CONDITION Diabetes was the highest cost traditional drug category, accounting for 11.9% of overall drug spend, with increases driven largely by unit cost inflation. Insulin agents, key drivers for diabetic trend, make up over 42% of diabetic drug spend and account for 18% of medication use. Metformin is the most utilized agent in the class, accounting for approximately 40% of medication use. Market share amongst the top 5 agents has seen negligible change from the previous year. Preferred formulations of metformin products, which have the same clinical effectiveness as other formulations, are 98% less costly. Aggressive formulary control of these metformin formulations resulted in a 58% unit cost decrease trend, which mitigated price inflation in brand diabetic drug classes. MARKET SHARE METFORMIN HCL METFORMIN HCL ER GLIMEPIRIDE LANTUS SOLOSTAR JANUVIA CATEGORY PMPY SPEND % OF TOTAL SPEND UTILIZATION UNIT COST TOTAL Diabetes $ % 3.6% 2.2% 5.8% Drug Trend Report 9

10 3. Multiple Sclerosis SPECIALTY CONDITION Oral MS agents continued to dominate the market share, accounting for 52% of medication use and 48% of drug spend. Most injectable MS agents experienced decreases in trend driven by decreases in utilization, signaling a shift from injectable to oral agents. Decrease in overall utilization is likely driven by shift to Ocrevus, typically handled through the medical specialty benefit. In, Ocrevus reported significant revenue and is considered by many as an impressive launch for a new molecular entity in the market. US Specialty Care has access to dispense Ocrevus, and costs are typically lower when this drug is filled under the pharmacy benefit than the medical benefit. Increase in unit cost was driven largely by double-digit increases in oral agents, particularly Tecfidera and Gilenya. Our MS Center of Excellence at US Specialty Care helps drive adherence and improve patient and provider communication and assessment of outcomes. Adherence at US Specialty Care continues to outperform industry standards, with an average PDC among the MS patients of over 92%. MARKET SHARE COPAXONE AMPYRA TECFIDERA AUBAGIO GILENYA CATEGORY PMPY SPEND % OF TOTAL SPEND UTILIZATION UNIT COST TOTAL Multiple Sclerosis $ % -1.2% 6.9% 5.7% Drug Trend Report 10

11 4. Oncology SPECIALTY CONDITION Oncology moved up in the ranking from 7th place to 4th place, due to double-digit trend, driven predominantly by double-digit increase in utilization. Increases in utilization is attributed largely to new drugs to market, particularly Rubraca, Zejula, Verzenio, Perjeta, Rydapt, and Kisqali. Increases in utilization were also attributed to expanded indications of several agents as first line agents, particularly for use in lung and breast cancer. Generic unit cost decreases for capecitabine and imatinib and significant increases in utilization, largely combatted increases seen with other agents. Drug mix, including increased use of available generic oncolytics, mitigated overall unit cost increase to only 5.3% despite double-digit unit cost increases in most branded agents. Targeted oncolytics have a better side effect profile and are better tolerated by patients, which results in slowing down disease progression with better quality of life and longer courses of therapy. MARKET SHARE CAPECITABINE REVLIMID IBRANCE TEMOZOLOMIDE RITUXAN CATEGORY PMPY SPEND % OF TOTAL SPEND UTILIZATION UNIT COST TOTA L Oncology $ % 20.6% 6.4% 27.0% Drug Trend Report 11

12 5. Asthma / COPD TRADITIONAL CONDITION Overall trend held at 1.2%, despite multiple new agents introduced in the treatment for COPD in. Drug mix and unit cost decreases of generic agents montelukast and levalbuterol contributed to negative unit cost in a category with multiple brand products Market share in the combination ICS products saw the beginning of a shift away from Advair and Symbicort to the newer agents. Enhanced price pressure amongst brand agents will continue to drive unit cost down. WellManaged-Respiratory, launching in 2018, is a new clinical program designed to help improve quality measures and clinical outcomes around asthma and COPD while controlling costs. Due to the multitude of similar clinically effective regimens in this category, the WellManaged - Respiratory program will include an aggressively managed formulary, adherence interventions, and patient education to ensure optimal clinical and financial outcomes. MARKET SHARE MONTELUKAST ADVAIR DISKUS SYMBICORT VENTOLIN HFA PROAIR HFA CATEGORY PMPY SPEND % OF TOTAL SPEND UTILIZATION UNIT COST TOTAL Asthma/COPD $ % 3.7% -2.5% 1.2% Drug Trend Report 12

13 6. High Blood Pressure TRADITIONAL CONDITION Approximately 50% of all medications utilized for high blood pressure are low-cost and highly effective generic medications. Significant unit cost decreases of generic Benicar (olmesartan) and Benicar combination products resulted in significant unit cost and overall trend reductions coupled with large increases in olmesartan utilization and decreases in brand Benicar. Utilization is expected to increase in 2018 due to recent release of updated guidelines from the ACC/AHA expanding the number of patients who should be treated compared to previous years. Approximately 22% of all high blood pressure agents experienced double-digit unit cost decreases, which contributed significantly to overall unit cost and trend reductions in this category. MARKET SHARE LISINOPRIL AMLODIPINE LOSARTAN HCTZ METOPROLOL SUCCINATE ER CATEGORY PMPY SPEND % OF TOTAL SPEND UTILIZATION UNIT COST TOTAL High Blood Pressure $ % -0.3% -18.6% -18.9% Drug Trend Report 13

14 7. HIV SPECIALTY CONDITION HIV as a therapeutic category rose 6 spots from 2016, from 13th to 7th based on PMPY. It also accounted for a larger portion of the total drug spend, Continued media attention Continued shift from the tenofovir disoproxil fumarate (TDF) for expanded prescribing and formulations to the tenofovir alafenamide (TAF) formulations coverage for pre-exposure contributed to the unit cost increases in this category. TAF formulations, prophylaxis may particularly Genvoya, Odefsey, and Descovy, experienced significant also have contributed to increases in utilization. increase in utilization. Truvada saw significant increase in utilization and market share in. Several new agents in 2018, such as Biktarvy and Trogarzo, are expected to impact this category. Despite FDA-approval for generic Truvada in, it is unclear when it will be commercially available due to ongoing patent litigation and negotiations. MARKET SHARE TRUVADA GENVOYA ATRIPLA STRIBILD TRIUMEQ CATEGORY PMPY SPEND % OF TOTAL SPEND UTILIZATION UNIT COST TOTAL HIV $ % 13.8% 14.9% 28.7% Drug Trend Report 14

15 8. Pain/Inflammation TRADITIONAL CONDITION Pain/Inflammation shifted from 6th place in 2016 to 8th place in, driven mostly by significant decreases in unit cost as well as utilization. Inappropriate prescribing of opioids, particularly transmucosal immediate-release fentanyl (TIRF) and long-acting agents, were key drivers in decreases associated with the WellManaged-Opioids program. Members in groups that were not managed showed a 36% higher average cost per 30-day supply of opioid medication. Unit cost decreases were largely due to expanded implementation by clients of WellManaged-Opioids and our Hyperinflationary Drug List. Preventing utilization of hyperinflationary medications, such as Duexis or Vimovo, which have readily available alternatives at substantially less cost were key drivers in decrease in unit cost for the Hyperinflationary Drug List program. MARKET SHARE HYDROCODONE / APAP MELOXICAM OXYCODONE / APAP IBUPROFEN TRAMADOL HCL CATEGORY PMPY SPEND % OF TOTAL SPEND UTILIZATION UNIT COST TOTAL Pain/Inflammation $ % -7.3% -26.0% -33.3% Drug Trend Report 15

16 9. High Blood Cholesterol TRADITIONAL CONDITION High blood cholesterol experienced the largest shift, with a drop from 4th most expensive to 9th. Significant decreases in unit cost drove the almost 39% decrease in trend in the category, driven largely by new to market generics for Zetia and Vytorin. Over 77% of the utilization in this category was for generically available statins, with atorvastatin at almost 40% of the market share. WellManaged-Generics aggressively managed utilization away from brand Crestor to its generic rosuvastatin, further driving down unit cost in the category. Non-statin therapies decreased from the previous year and comprise a small percentage of overall use. Updated ACC/AHA Cholesterol treatment guidelines are slated to be released in 2018, which may have further impact on utilization patterns in this category. MARKET SHARE FENOFIBRATE ATORVASTATIN PRAVASTATIN ROSUVASTATIN SIMVASTATIN CATEGORY PMPY SPEND % OF TOTAL SPEND UTILIZATION UNIT COST TOTAL High Blood Cholesterol $ % -0.1% -38.8% -38.9% Drug Trend Report 16

17 10. Attention Disorder TRADITIONAL CONDITION New generics for Strattera (atomoxetine) and increased generic price competition among guanfacine ER, armodafinil, and modafinil contributed to decreases in unit cost. WellManaged-Generics helped drive generic utilization in this category, with 4 out of the top 5 as generic agents. Overall in the category, the generic dispensing rate (GDR) was 75%, an increase of almost 5% from the previous year. It is estimated that for every 1% increase in generic dispensing, there is approximately 4% in savings. MARKET SHARE METHYLPHENIDATE AMPHETAMINE/ DEXTROAMPHETAMINE GUANFACINE ER METHYLPHENIDATE ER VYVANSE CATEGORY PMPY SPEND % OF TOTAL SPEND UTILIZATION UNIT COST TOTAL Attention Disorder $ % 3.1% -3.3% -0.2% Drug Trend Report 17

18 Methodology Trend: Represents change for Total Costs PMPY (total plan and member pay) for from 2016 for WellDyneRx commercial book of business and is net of rebates. Utilization: Represents the change in day supply PMPY year over year. Unit Cost: Represents the change in Total Cost per day supply year over year, net of rebates received by plans. About WellDyneRx WellDyneRx is a full-service Pharmacy Benefit Manager (PBM) that makes the little things matter for its clients, employees, partners, and members. WellDyneRx provides members with more than 66,000 retail pharmacies across the U.S.; mail order prescription services with the capacity to fulfill more than 15 million prescriptions per year; a wholly-owned specialty pharmacy (www. USSpecialtyCare.com) to focus on expensive specialized drugs; and highly targeted pharmacy programs for Diabetes, Hepatitis C and Opioids to balance optimal clinical outcomes with minimized plan costs. Visit to learn how you can optimize your health plan today. Note: Plans were excluded if they were not clients for all of 2016 and or if they had 100% or 0% copayment benefits. Minimum essential coverage (MEC) clients were also excluded. In most cases, results are rounded down to one decimal for easier reading. Drug Trend Report 18

19

2017 Drug Trend Report Commercial Medicare Medicaid Exchanges

2017 Drug Trend Report Commercial Medicare Medicaid Exchanges 2017 Drug Trend Report Commercial Medicare Medicaid Exchanges Leading the way for patients and plans Our clients place a great deal of trust in Express Scripts. They ask us to care for their plan members

More information

2016 Drug Trend Report COMMERCIAL

2016 Drug Trend Report COMMERCIAL 2016 Drug Trend Report COMMERCIAL THERAPY CLASS REVIEW MARKET FACTORS METHODOLOGY Table of contents Introduction 3 Therapy class review 6 Bending the curve on drug spending in 2016 7 Top 15 therapy classes

More information

2016 Drug Trend Report MEDICARE

2016 Drug Trend Report MEDICARE 2016 Drug Trend Report MEDICARE 2016 Drug Trend Report Medicare Introduction 3 Trend analysis 6 Keeping spending increases in check for America s seniors 7 Medicare Advantage Prescription Drug Plan (MAPD)

More information

F Y 1 8 U T I L I Z A T I O N R E V I E W 7/1/2017 TO 3/31/2018 L O C K T O N C O M P A N I E S

F Y 1 8 U T I L I Z A T I O N R E V I E W 7/1/2017 TO 3/31/2018 L O C K T O N C O M P A N I E S UNIVERSITY OF ALASKA F Y 1 8 U T I L I Z A T I O N R E V I E W 7/1/2017 TO 3/31/2018 L O C K T O N C O M P A N I E S Premera - Medical L O C K T O N C O M P A N I E S Medical Utilization % Change Norm

More information

F Y 1 9 U T I L I Z A T I O N R E V I E W 7/1/2018 TO 9/30/2018 L O C K T O N C O M P A N I E S

F Y 1 9 U T I L I Z A T I O N R E V I E W 7/1/2018 TO 9/30/2018 L O C K T O N C O M P A N I E S UNIVERSITY OF ALASKA F Y 1 9 U T I L I Z A T I O N R E V I E W 7/1/2018 TO 9/30/2018 L O C K T O N C O M P A N I E S Premera- Medical L O C K T O N C O M P A N I E S Medical Utilization % Change Norm FY18

More information

Prescription Benefit Management. Eric Cannon, PharmD, FAMCP

Prescription Benefit Management. Eric Cannon, PharmD, FAMCP Prescription Benefit Management Eric Cannon, PharmD, FAMCP Agenda Drugs as a Share of Health Spending Top Drugs of 2016 Management Interventions and Strategies Specialty Pharmacy, Generics and Biologics

More information

Medication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes

Medication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes Medication trends shaping workers compensation A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes OPTUM WORKERS COMPENSATION DATA SET Analysis of our data, the industry

More information

Medication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes

Medication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy

More information

2017 Drug Trends Series

2017 Drug Trends Series 2017 Drug Trends Series Part 1 Evaluating the traditional view Retail and mail-order prescriptions Published April 2018 1 2017 Drug Trends Series Traditional View First Script A year of important progress

More information

2016 Drug Trends Series

2016 Drug Trends Series Drug Trends Series Part 3: Assessing opioids and compounds Published August 2017 1 Drug Trends Series Opioids & Compounds First Script Introduction As with the first two editions in Coventry s Drug Trends

More information

MArch The 2014 Drug Trend Report Highlights

MArch The 2014 Drug Trend Report Highlights MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers

More information

The power of partnership.

The power of partnership. School Board of Clay County and UnitedHealthcare. Building health ownership together. December 13, 2017 Annual Healthplan Performance Review October 1, 2016 thru September 30, 2017 Let s get started inspiring

More information

PRESCRIPTION DRUG TREND REPORT

PRESCRIPTION DRUG TREND REPORT EXPRESS SCRIPTS CANADA PRESCRIPTION DRUG TREND REPORT TRENDS IN CANADIAN PRIVATE DRUG SPEND Express Scripts Canada, 2018. All Rights Reserved TABLE OF CONTENTS EXECUTIVE SUMMARY... 3 METHODOLOGY AND TERMINOLOGY...

More information

Pharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica

Pharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica Pharmacy Trends and Management Opportunities Kerry Bendel, R.Ph. Director of Pharmacy Medica September 14, 20 1 Agenda Pharmacy Trend Experience Trend Drivers and Management Opportunities Call to Action

More information

JOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE

JOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE JOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE PASBO S STATEWIDE DATA STRATEGY WITH INNOVU PASBO 62 ND ANNUAL CONFERENCE AND EXHIBITS, PITTSBURGH 1 DATA STRATEGY PLATFORM 2 1 WHAT ARE

More information

taking at (Jan. 21, 2016) by Older 2016.pdf).

taking at (Jan. 21, 2016) by Older 2016.pdf). HSGAC MINORITY STAFF REPORT MANUFACTURED CRISIS How Devastating Drug Increases Are Harming America s Seniors U.S. Senate Homeland Security & Governmental Affairs Committee, Minority Office Page 1 EXECUTIVE

More information

Q&A for Group Administrators: Wellmark Announces Strategic Pharmacy Program Changes to Help Control Drug Spend

Q&A for Group Administrators: Wellmark Announces Strategic Pharmacy Program Changes to Help Control Drug Spend Learn More Q&A for Group Administrators: Wellmark Announces Strategic Pharmacy Program Changes to Help Control Drug Spend Iowa and South Dakota Pharmacy Benefit Plans This document answers questions regardingupcoming

More information

April 2o14. The 2013 Drug Trend Report Highlights

April 2o14. The 2013 Drug Trend Report Highlights April 2o14 The 2013 Drug Trend Report Highlights Express Scripts Reports Lowest Specialty Drug Trend Since 2007 In 2013, spending on prescription drugs increased 5.4% after several years of slower-paced

More information

PharmaSuitables October Rich Price, MD Zach Kareus, Pharm.D. Steve Nolan, Pharm.D.

PharmaSuitables October Rich Price, MD Zach Kareus, Pharm.D. Steve Nolan, Pharm.D. PharmaSuitables October 2017 Rich Price, MD Zach Kareus, Pharm.D. Steve Nolan, Pharm.D. Disclosures Rich, Zach, and Steve work for Rocky Mountain Health Plans. We do not have any financial interest in

More information

PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars

PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was

More information

Well Informed. A Comprehensive Approach to Pain Management. Pain Guardian

Well Informed. A Comprehensive Approach to Pain Management. Pain Guardian Q1 2 0 1 7 Well Informed A Comprehensive Approach to Pain Management Use of opioids is common and necessary to support treatment for a wide variety of health related issues; however, the use of opioid

More information

Cyber Liability and Crime Update

Cyber Liability and Crime Update Cyber Liability and Crime Update Cyber Liability Probability of a Data Breach 2 3 Cyber Liability Challenges Carriers are not as forthcoming with sharing data as we would like to see Large uptick in ransomware

More information

Case Study. GlucosePATH shows the way to improved outcomes and $1.1MM in employer drug cost savings

Case Study. GlucosePATH shows the way to improved outcomes and $1.1MM in employer drug cost savings Case Study GlucosePATH shows the way to improved outcomes and $1.1MM in employer drug cost savings Background A self-insured company has 600 employees with Type 2 Diabetes The company asked if GlucosePATH

More information

MArch The 2014 Drug Trend Report MEDICARE

MArch The 2014 Drug Trend Report MEDICARE MArch 2015 The 2014 Drug Trend Report MEDICARE content MedicaRE 3 Medicare Year in Review A Look at Medicare Overall Drug Trend for 2014 Medicare: Traditional Therapy Classes and Insights Top 10 Medicare

More information

PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS

PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS For Producer Audience Only - Please Do Not Distribute Regence has selected Prime Therapeutics as the Pharmacy benefits manager for its health plans.

More information

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs

More information

Magellan Rx. A smarter approach to pharmacy benefits management

Magellan Rx. A smarter approach to pharmacy benefits management Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We

More information

The Opioid Epidemic and How It is Impacting the Workplace. July 24, 2018

The Opioid Epidemic and How It is Impacting the Workplace. July 24, 2018 The Opioid Epidemic and How It is Impacting the Workplace July 24, 2018 In 2016 CDC reports a 300% increase in opioid prescription sales since 1999 without an overall change in reported pain National Safety

More information

Strengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018

Strengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements

More information

Market Potential for MDX Alcobra Investor Breakfast July 15, 2014

Market Potential for MDX Alcobra Investor Breakfast July 15, 2014 Market Potential for MDX Alcobra Investor Breakfast July 15, 2014 Forward Looking Statement This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases,

More information

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs

More information

Understanding Your Patient Care Opportunity Report (PCOR)

Understanding Your Patient Care Opportunity Report (PCOR) Understanding Your Patient Care Opportunity Report (PCOR) Use your January/February 208 PCOR to help improve performance on Medicare Part D Clinical Star Ratings measures. Your January/February 208 Patient

More information

Save on your drugs with HealthyRx

Save on your drugs with HealthyRx Save on your drugs with HealthyRx HealthyRx is a savings program offered through the UVa Hoo s Well program. It helps lower your costs on drugs for certain health conditions. Effective 4/1/17, you are

More information

Safe, effective, affordable drug choices: online tool for payers and patients.

Safe, effective, affordable drug choices: online tool for payers and patients. Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers

More information

Medicaid Perspective

Medicaid Perspective Prescription Opioid Fraud and Abuse: Medicaid Perspective Presenter: Gary P. Gilmore, B.S., R.Ph. Director, Analysis & Reporting Office of Clinical Affairs Deputy Director, Pharmacy Program Objectives:

More information

Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable.

Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable. Are Specialty Pharmacy Drugs Worth the Cost? How Companies Can Make Them More Affordable. BACKGROUND Your Host: Eric Bricker, MD Co-Founder & Chief Medical Officer - Compass Professional Health Services

More information

Update to HMO Drug Formulary Tier Definitions. February 8, 2018

Update to HMO Drug Formulary Tier Definitions. February 8, 2018 Update to HMO Drug Formulary Tier Definitions February 8, 2018 Agenda 1 Overview of Current Drug Tiers 2 Proposed Drug Tiers for 2019 3 Impact to SFHSS and SFHSS Members 4 How the Drug Formulary Works

More information

Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA

Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.

More information

Market Distortions from the 340B Drug Pricing Program

Market Distortions from the 340B Drug Pricing Program Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect

More information

Mediscor Medicines Review 2011

Mediscor Medicines Review 2011 Mediscor Medicines Review 2011 Mediscor Client Workshop 2012 28 August 2012 Presented by: Madelein Bester Benefit Management Mediscor PBM Content Background of the report Overall trends Expenditure per

More information

REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 FASIGLIFAM (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 FASIGLIFAM (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 Executive Summary Fasiglifam (TAK-875): Key Metrics in the 10 Major Pharmaceutical Markets* 2022 Market Sales US $508m 5EU $127m Japan $30m China $341m

More information

Insulins: Prices, Rebates, and Other Factors Influencing Costs. May 2018

Insulins: Prices, Rebates, and Other Factors Influencing Costs. May 2018 Insulins: Prices, Rebates, and Other Factors Influencing Costs May 2018 Introduction: Types of Insulin Types of Insulin Rapid-acting: Usually taken before a meal to cover the blood glucose elevation from

More information

Summary of Related Documentation Pennsylvania House Bill 1846 of 2014

Summary of Related Documentation Pennsylvania House Bill 1846 of 2014 Summary of Related Documentation Pennsylvania House Bill 1846 of 2014 15 November 2018 Department of Labor & Industry BWC-Administrative Division 1171 S. Cameron St. Harrisburg PA 17104-2501 Essential

More information

How pharmacy and retail health can support health and wellness. Nancy Gagliano Chief Medical Officer, MC September, 2014

How pharmacy and retail health can support health and wellness. Nancy Gagliano Chief Medical Officer, MC September, 2014 How pharmacy and retail health can support health and wellness Nancy Gagliano Chief Medical Officer, MC September, 2014 2 An important decision for public health Current Health Care Challenges The State

More information

The use of high cost or Nonpreferred Brand drugs is contributing to higher overall costs for your group. Consider the following to reduce costs:

The use of high cost or Nonpreferred Brand drugs is contributing to higher overall costs for your group. Consider the following to reduce costs: April 22, 2014 Sandy Randall Dear Ms. Randall: Enclosed are 4 th Quarter 2013 reports that analyze the major parameters of drug utilization by Rocky Mountain Health Plans (RMHP) Members within the. Graphs

More information

Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015

Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015 Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs 1 June 5, 2015 Introductions Mark Steck Pharm.D Independent Consultant, MAXIMUS John J.P. Crouse Vice President, MAXIMUS Market Lead

More information

Cost-Motivated Treatment Changes in Commercial Claims:

Cost-Motivated Treatment Changes in Commercial Claims: Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical

More information

Managing Opioid Overutilization Challenges

Managing Opioid Overutilization Challenges One Source. Lower Cost. Better Care. Managing Opioid Overutilization Challenges A LOOK AT REDUCING OPIOID OVERUTILIZATION BY 36 PERCENT Copyright 2017 MedImpact Healthcare Systems, Inc. All rights reserved.

More information

CONFRONTING THE OPIOID EPIDEMIC. e-book: Introducing OptumRx Opioid Risk Management

CONFRONTING THE OPIOID EPIDEMIC. e-book: Introducing OptumRx Opioid Risk Management CONFRONTING THE OPIOID EPIDEMIC 2 0 1 8 OPIOID ABUSE IS A CRISIS IN THE U.S. OptumRx Opioid Risk Management attacks this complex, deeply embedded problem with a comprehensive approach featuring five interrelated

More information

Pharmacy Benefit Solutions 2010 Trend Report

Pharmacy Benefit Solutions 2010 Trend Report Pharmacy Benefit Solutions 2010 Trend Report Here we share pharmacy benefit trend Presenting management our PBM performance trend performance the for the past past year year and a glimpse into the future.

More information

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18

Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance requires step therapy for certain drugs. This means prior to receiving a drug with a step therapy

More information

BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES

BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.

More information

Self-Insurance 2016 Q2 Update. Presented by Marcy Syman, Human Resources Director

Self-Insurance 2016 Q2 Update. Presented by Marcy Syman, Human Resources Director Self-Insurance 2016 Q2 Update Presented by Marcy Syman, Human Resources Director Management Committee 9-12-2016 Dollars in Millions Self-Insured Plan Costs Q2 2016 (Claims, admin fees and stop loss premium)

More information

Have you been paying for your prescription drugs? Stop!

Have you been paying for your prescription drugs? Stop! Dear Valued Medtipster Member: Have you been paying for your prescription drugs? Stop! Free prescription drugs are NOW just a Medtipster ID card away. Follow the steps below to obtain thousands of generic

More information

UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008

UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 UF Decision Report FY06-07 Beneficiary Advisory Panel 10 Jan 2008 Promoting high quality, cost effective drug therapy throughout the Military Health System UF Decisions, May 07 Class FY05 rank, total $

More information

New Guidelines for Prescribing Opioids

New Guidelines for Prescribing Opioids New Guidelines for Prescribing Opioids Keeping Your Claimants Safe Presented by: Dr. Mitch Freeman, Pharm.D. Chief Clinical Officer, Pharmacy Solutions Agenda The Opioid Challenge Today How We Got Here

More information

THERAPEUTIC AREA NAME STRENGTH DOSAGE FORM

THERAPEUTIC AREA NAME STRENGTH DOSAGE FORM Value Based Tier Drugs are selected for the management of Asthma, Diabetes, Hypertension and Hyperlipidemia. These drugs are covered at no charge or at a reduced cost share. Medications are under continual

More information

Specialty Drugs in Workers Compensation

Specialty Drugs in Workers Compensation Specialty Drugs in Workers Compensation A GUIDE FOR CLAIMS HANDLERS Specialty Drugs Specialty drugs have been developed in response to demand for specialized medications for complex medical conditions.

More information

2018 Travelers Prescription Drug Plan High Deductible + HSA Plan

2018 Travelers Prescription Drug Plan High Deductible + HSA Plan 2018 Travelers Prescription Drug Plan High Deductible + HSA Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that section National Preferred Formulary

More information

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

Specialty conditions overview

Specialty conditions overview Specialty conditions overview Prevalence and cost Click on the vials to learn more about these specialty conditions. 1. Approximate annual AWP cost per patient of top utilized drugs for UHC calendar year

More information

THE GROWTH OF SPECIALTY PHARMACY

THE GROWTH OF SPECIALTY PHARMACY UnitedHealth Center for Health Reform & Modernization THE GROWTH OF SPECIALTY PHARMACY Current trends and future opportunities Issue Brief April 2014 Summary Innovative specialty drugs are providing important

More information

Understanding the Value of Generic Drugs

Understanding the Value of Generic Drugs Understanding the Value of Generic Drugs Generic drugs can help you get the most out of your health care budget. 05.02.306.1 (8/05) Many people believe that when something costs more, it must be of higher

More information

September 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic

September 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC 20036 RE: Prescription Opioid Epidemic On behalf of America s Health Insurance Plans (AHIP), thank you for your leadership

More information

Oregon Health Plan prescription benefit updates

Oregon Health Plan prescription benefit updates Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save

More information

Pharmacy benefit guide

Pharmacy benefit guide FlexRx SM 5-Tier Pharmacy benefit guide 1 Welcome to FlexRx The NHP FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many common medications

More information

Datamonitor Healthcare Pharma intelligence. GlaxoSmithKline: Company Analysis

Datamonitor Healthcare Pharma intelligence. GlaxoSmithKline: Company Analysis Datamonitor Healthcare Pharma intelligence GlaxoSmithKline: Company Analysis OVERVIEW Latest Earnings Review Q2 2018 [27 July 2018] Click to view analysis Latest Forecast Update Q2 2018 [2 August 2018]

More information

61 Recommendations for better use of medications

61 Recommendations for better use of medications Chapter 61 Recommendations for better use of medications As stated elsewhere in this book, we are fortunate to have a number of effective medications for treatment of many medical conditions. The drug

More information

Evaluation of Specialty Pharmacy in an Integrated Health-System

Evaluation of Specialty Pharmacy in an Integrated Health-System Evaluation of Specialty Pharmacy in an Integrated Health-System Emma Chermely, PharmD, BCACP Alyssa McCann, PharmD, BCACP *The presenters have no conflicts of interest to disclose. Objectives Introduce

More information

STEP THERAPY IN MEDICARE PART D

STEP THERAPY IN MEDICARE PART D STEP THERAPY IN MEDICARE PART D Sarkis Kavarian, PharmD Candidate 15 Preceptor Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. May 1 st, 2015 Objectives Why is this important? Medicare Part

More information

Dear Member: We look forward to serving you. Sincerely, Express Scripts

Dear Member: We look forward to serving you. Sincerely, Express Scripts Dear Member: Welcome to Express Scripts, the company Eastern Kentucky University has chosen to manage your prescription drug plan. As one of the nation s leading prescription benefit managers, Express

More information

Do OurHealth primary care clinics improve health & reduce healthcare costs? OurHealth Patient Engagement Analysis June 2018

Do OurHealth primary care clinics improve health & reduce healthcare costs? OurHealth Patient Engagement Analysis June 2018 Question: Do OurHealth primary care clinics improve health & reduce healthcare costs? OurHealth Patient Engagement Analysis June 2018 An examination of health improvements, utilization & cost of care for

More information

Myriad Genetics Corporate Presentation 06/13/2018

Myriad Genetics Corporate Presentation 06/13/2018 Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today

More information

WellINFORMED. From the PRESIDENT S DESK. Every Little Thing Brings BIG OUTCOMES.

WellINFORMED. From the PRESIDENT S DESK. Every Little Thing Brings BIG OUTCOMES. WellINFORMED From the PRESIDENT S DESK At WellDyneRx, we believe that every little thing brings big outcomes. We re committed to optimizing and enhancing every health plan, every prescription fill, and

More information

2014 DTC National Advertising Awards Finalists

2014 DTC National Advertising Awards Finalists 2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,

More information

Pharmacy Costs: Can I Make a Difference?

Pharmacy Costs: Can I Make a Difference? Pharmacy Costs: Can I Make a Difference? Pharmaceutical Market Dynamics What is driving Rx cost up? No New Blockbusters Patent Expirations OTC Market Dynamics Availability Pharmaceutical Companies Unfortunately,

More information

Clinical Policy: Step Therapy Reference Number: CP.PST.01 Effective Date: Last Review Date: 11.18

Clinical Policy: Step Therapy Reference Number: CP.PST.01 Effective Date: Last Review Date: 11.18 Clinical Policy: Reference Number: CP.PST.01 Effective Date: 12.28.17 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory

More information

The Sustainability of Irish Pharmaceutical Expenditure. Valerie Walshe Ph.D. Economist

The Sustainability of Irish Pharmaceutical Expenditure. Valerie Walshe Ph.D. Economist The Sustainability of Irish Pharmaceutical Expenditure Valerie Walshe Ph.D. Economist valerie.walshe@hse.ie February 2015 Content Overview of Irish Health Services Community Drug Prescribing Trends Driving

More information

2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan

2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan 2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that

More information

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Speaker Brian K. Solow, MD, FAAFP Optum Life Sciences Irvine, CA, USA PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S. Brian K. Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences

More information

Clinical Policy: Step Therapy Reference Number: CP.PST.01 Effective Date: Last Review Date: 02.19

Clinical Policy: Step Therapy Reference Number: CP.PST.01 Effective Date: Last Review Date: 02.19 Clinical Policy: Reference Number: CP.PST.01 Effective Date: 12.28.17 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory

More information

January 16, Dear Administrator Verma:

January 16, Dear Administrator Verma: Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMMI New Direction P.O. Box 8011 Baltimore, MD 21244-1850 Re: (CMS-4182-P) Medicare

More information

Practice Advisory on Drug Coverage Parity across Medical and Pharmacy Benefits

Practice Advisory on Drug Coverage Parity across Medical and Pharmacy Benefits Practice Advisory on Drug Coverage Parity across Medical and Pharmacy Benefits Introduction Oncology medications have historically been administered intravenously in a physician s office, infusion center

More information

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017 Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017 DRUG LIST CHANGES Based on the availability of new prescription medications and Prime s National Pharmacy and Therapeutics Committee

More information

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite

More information

Strategies for Federal Agencies

Strategies for Federal Agencies Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid

More information

Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes

Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes Date: October 3, 2017 To: Participating Providers From: YourCare Health Plan Provider Relations Subject: 2018 Formulary Changes 2018 Formulary-UM Changes What does this mean now, and for 2018? A number

More information

Coverage Period: 01/01/ /31/2018 Coverage for: Individual and/or Family Plan: Healthy Rewards HSA

Coverage Period: 01/01/ /31/2018 Coverage for: Individual and/or Family Plan: Healthy Rewards HSA This is only a summary of your GatorCare pharmacy benefits. If you would like detail about your coverage and costs, you can get the complete terms in the policy or plan document at gatorcare.magellanrx.com/member

More information

Partnering for Growth

Partnering for Growth Partnering for Growth JP Morgan Healthcare Conference Simon Lowth, Chief Financial Officer, AstraZeneca 9 January 2013 Partnering for Growth Agenda Our platforms for growth Partnering strategy and capabilities

More information

Best Practices for Specialty Pharmacy Usage Management. Neil S. Shah, PharmD Specialty Pharmacist, Blue Cross Blue Shield of NC

Best Practices for Specialty Pharmacy Usage Management. Neil S. Shah, PharmD Specialty Pharmacist, Blue Cross Blue Shield of NC Best Practices for Specialty Pharmacy Usage Management Neil S. Shah, PharmD Specialty Pharmacist, Blue Cross Blue Shield of NC Overview Provide a background to specialty pharmacy Identify key industry

More information

9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance

9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance Pharmacy Quality Measures: Action Steps for Improvement Financial Support Financial support was provided for this activity through an unrestricted grant from Health Mart Systems, Inc. Christine Jacobson

More information

Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017

Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017 Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017 Scottish Health Protection Network HIV Clinical Leads FINAL Approved for circulation 17 May 2017 Version No. 6.2 (04/05/17) Date

More information

Mail Order Is Not For Everyone!

Mail Order Is Not For Everyone! Mail Order Is Not For Everyone! Face to face patient counseling by pharmacists can have a powerful impact on long term health care costs and quality. So, the way health plan sponsors promote mail and generics

More information

Dental insurance: A bright idea for your business

Dental insurance: A bright idea for your business Dental insurance: A bright idea for your business Many challenges, one solution Your business faces a variety of challenges every day. Fortunately, you can solve many of them through one solution: offering

More information

The Value of Walgreens

The Value of Walgreens The Value of Walgreens How Walgreens improves employer health plans through access, quality and lower costs Why millions of patients choose Walgreens And your options to move forward with Walgreens Walgreens

More information

Reason for change. Recently approved. Recently approved. Recently approved. Recently approved. Recently updated. Recently approved.

Reason for change. Recently approved. Recently approved. Recently approved. Recently approved. Recently updated. Recently approved. 2017 Formulary Change Notice Please note these changes to your 2017 List of Covered Drugs Drug name (medication) Rubraca Aprepitant Onivyde Oseltamivir Restasis Xiidra Daptomycin Selzentry Linzess Butalb/APAP/caff

More information

Find out more at: OUR MISSION

Find out more at:   OUR MISSION Find out more at: www.gilead.com/yir2017 SCIENTIFIC INNOVATION & ADDRESSING UNMET NEEDS Gilead uses its scientific expertise to help transform and simplify care for people with life-threatening illnesses

More information